Clinical trials: AMD
Age-related Macular Degeneration, Choroidal Neovascularization
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to…
- Trial name
- NCT00712491
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Santen Inc.
Macular Degeneration, Choroidal Neovascularization
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib…
- Trial name
- VERITAS (NCT00242580)
- Testing
- Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age-related Macular Degeneration
Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration
The study aims to investigate the effectiveness of Eylea in patients with wet age-related macular degeneration in routine clinical practice in Germany.
- Trial name
- PERSEUS (NCT01914380)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Germany
- Volunteers
- 988 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration
A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration
This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients with wet AMD.
- Trial name
- NCT03814291
- Testing
- IBI302
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Age-Related Macular Degeneration (AMD)
EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).
This prospective, observational, open-label study evaluates early treatment response to intravitreal aflibercept 8 mg in patients with exudative age-related macular degeneration.
- Trial name
- ELEV8 (NCT07434713)
- Testing
- treatment with Aflibercept 8mg (Eylea)
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO)
Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases
The study compares the perceived treatment burden in patients undergoing intravitreal anti-VEGF treatment for either wet age related macular degeneration, macular edema after retinal vein occlusions or diabetic macular edema.
- Conditions
- Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME)
- Trial name
- NCT07514559
- Where
- Austria
- Volunteers
- 393 people
- Sponsor
- Hospital Hietzing
Macular Degeneration, Wet, Metamorphopsia
M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD
Age-related macular degeneration (AMD) is a complex eye disorder and the most common macular disease affecting millions of aged people in the developed countries, with an estimation that the number of AMD patients will be…
- Trial name
- MVAinAMD2022 (NCT05324150)
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Choroidal Neovascularization, Macular Degeneration
Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration
Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. The major cause of vision loss in this disease is due to the development of choroidal neovascular membrane…
- Trial name
- NCT00001615
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Eye Institute (NEI)
Glycogen Storage Disease Type II, Pompe's Disease
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD
This is a single group, 52-week treatment, Phase 4, open-label, single-arm study to assess the safety and efficacy of avalglucosidase alfa IV infusion in male and female Chinese participants with IOPD who are treatment-naïve or…
- Trial name
- NCT06666413
- Testing
- Avalglucosidase alfa
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Genzyme, a Sanofi Company
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with…
- Trial name
- HAWK (NCT02307682)
- Testing
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Where
- United States
- Volunteers
- 1,775 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
The purpose of the study is to evaluate the safety, tolerability, immunogenicity, and bioactivity of a single intravitreal (IVT) administration of DE-122 in subjects with refractory exudative age-related macular degeneration…
- Trial name
- PAVE (NCT02555306)
- Testing
- 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Santen Inc.
Geographic Atrophy, Dry Age-Related Macular Degeneration
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration…
- Trial name
- NCT02686658
- Testing
- Avacincaptad Pegol
- Where
- 78 sites in United States, Croatia and 5 more
- Volunteers
- 286 people
- Sponsor
- IVERIC bio, Inc.
Age-Related Macular Degeneration, Lens, Intraocular
Implantation of SML in Patients With Dry Age-related Macular Degeneration and Myopic Maculopathy
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in developed countries among people over 50 years of age. Myopic maculopathy is also an important cause of irreversible vision loss.
- Conditions
- Age-Related Macular Degeneration, Lens, Intraocular, Myopic Maculopathy
- Trial name
- NCT03882606
- Testing
- Scharioth Macula Lens (SML, Medicontur)
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Consorci Sanitari de Terrassa
Diabetes Mellitus, Macular Edema
Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema
To evaluate the effect of alpha lipoic acid (ALA) on the occurrence of diabetic macular edema.
- Trial name
- RETIPON (NCT01208948)
- Testing
- 1,2 dithiolane 3 valeric acid
- Where
- Germany
- Volunteers
- 520 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Age-Related Macular Degeneration
Genetic Study of Age-Related Macular Degeneration
This study will examine skin and blood cells for genetic changes related to the development of age-related macular degeneration, an eye disease that can significantly impair the ability to read, drive, and carry out daily…
- Trial name
- NCT00357578
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Geographic Atrophy
A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.
- Trial name
- NCT01603043
- Testing
- Al-78898A
- Volunteers
- 10 people
- Sponsor
- Alcon Research
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to the contralateral (second) eye of adult participants (≥ 50 years of…
- Trial name
- NCT07630649
- Testing
- Ixo-vec
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Adverum Biotechnologies, Inc.
Macular Degeneration Exudative Eye Left, Macular Degeneration Exudative Eye Right
OCTA (Optical Coherence Angiography Tomography) Versus Structural OCT(Optical Coherence Tomography) in Neovascular AMD (Age Macular Degeneration)
The objective is to find if there is a relationship between the Fractal Dimension, the gap, vascular density (VD), the surface, the span ratio and the status of the choroidal neovessels to adjust the interval between 2…
- Trial name
- QUAOBARE (NCT03939195)
- Testing
- Follow-up
- Where
- 3 sites in France
- Volunteers
- 130 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Diabetic Retinopathy, Age-Related Macular Degeneration (AMD)
Genetics and Markers of Degenerative and Inflammatory Eye Diseases
This study will identify genes that are associated with inflammation or degeneration of the retina (membrane lining the back of the eye that relays vision signals to the brain).
- Conditions
- Diabetic Retinopathy, Age-Related Macular Degeneration (AMD), Uveitis
- Trial name
- NCT00647439
- Where
- United States
- Volunteers
- 609 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients
Primary objective: To evaluate the change in aqueous humor vascular endothelial growth factor A (VEGF-A) levels after 2 months of initial treatment with 8 mg Aflibercept in treatment-naïve nAMD patients.
- Trial name
- NCT07728981
- Testing
- Aflibercept 8mg
- Volunteers
- 49 people
- Sponsor
- Tianjin Medical University Eye Hospital